MAT2B and breast cancer: Furthermore, BC patients with low expressions of DNMT3B and AHCYL1 had higher IPS, indicating that these patients had higher relative probabilities of responding to ICIs, whereas BC patients with high expressions of MAT2B, CHKB, and SHMT2 had higher relative probabilities of responding to ICIs (Figure 8D).